AbbVie Downplays Impact Of Viekira Pak Safety Issues
This article was originally published in The Pink Sheet Daily
Because Child-Pugh B cirrhotic patients are such a small portion of hepatitis C population, AbbVie predicts labeling update won't make a material difference in sales; outreach to clinicians and health plans is going well, CEO Gonzalez adds.
You may also be interested in...
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
IBA’s name change refines its identity as the representative of the independent and entrepreneurial beauty industry, according to the trade organization’s announcement. The group’s FDA Cosmetics Regulation Workshop, held annually since 1983 in cooperation with the FDA, will be virtual in 2020.